Vol 6, No 3 (2010)
Case report
Published online: 2010-08-27
Long-term treatment with trastuzumab of patient with skin metastatic breast cancer — a case report
Onkol. Prak. Klin 2010;6(3):113-115.
Abstract
Trastuzmab is the treatment of choice for HER2-overexpressing metastatic breast cancer. The treatment
is well tolerated. Despite the fact that trastuzumab is used commonly, duration of the treatment has not
been defined. Case of 46-year old female patient on continuous 5 year trastuzumab was described.
Onkol. Prak. Klin. 2010; 6, 3: 113–115
Onkol. Prak. Klin. 2010; 6, 3: 113–115
Keywords: metastatic breast cancertrastuzumab
References
- Jones RL, Smith IE. Efficacy and safety of trastuzumab. Expert Opin Drug Saf. 2004; 3(4): 317–327.
- Adamo V, Franchina T, Adamo B, et al. Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study). Ann Oncol. 2007; 18 Suppl 6: vi11–vi15.
- Sawaki M, Ito Y, Tada K, et al. Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER-2/neu-overexpressing metastatic breast cancer. Tumori. 2004; 90(1): 40–43.
- Eichbaum MHR, Schneeweiss A, Bastert G. Long-term remission of excessive liver metastases in a breast cancer patient with chronic alcohol abuse using a monotherapy with trastuzumab. Anticancer Drugs. 2005; 16(2): 199–200.
- Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20(3): 719–726.
- McKeage K, Perry CM. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs. 2002; 62(1): 209–243.
- Ewer MS, O'Shaughnessy JA. Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer. Clin Breast Cancer. 2007; 7(8): 600–607.
- Strevel EL, Siu LL. Cardiovascular toxicity of molecularly targeted agents. Eur J Cancer. 2009; 45 Suppl 1: 318–331.
- Shaffer R, Tyldesley S, Rolles M, et al. Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: a retrospective single-institution study. Radiother Oncol. 2009; 90(1): 122–126.
- Beda M, Basso U, Ghiotto C, et al. When should trastuzumab be stopped after achieving complete response in HER2-positive metastatic breast cancer patients? Tumori. 2007; 93(5): 491–492.